Dated: March 16, 1995.

Margery G. Grubb,

Senior Committee Management Specialist, NIH.

[FR Doc. 95–7229 Filed 3–23–95; 8:45 am]

BILLING CODE 4140–01–M

Office of Research on Women's Health; Notice of Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of a meeting of the Advisory Committee on Research on Women's Health to be held April 24 and 25, 1995 in Conference Room D of the Natcher Conference Center (Building 45), 45 Center Drive, Bethesda, Maryland 20892. The meeting will be held from 10 am to 5 pm on April 24 and from 8:30 am to 12 pm on April 25. The meeting is open to the public, with attendance limited to space available.

The purpose of the meeting will be to familiarize the Committee members with the operations and programs of the Office of Research on Women's Health, Office of the Director, National Institutes of Health. The agenda will include: (1) A discussion of the Committee's duties and responsibilities and (2) reports on ORWH activities and programs.

Rosemary Torres, J.D., B.S.N., Special Assistant to the Director, Office of Research on Women's Health, OD, NIH, Building 1, Room 209, Bethesda, Maryland 20892, 301–402–1770, 301–402–1798 (FAX), will furnish the meeting agenda, roster of Committee members, and substantive program information upon request. Individuals who plan to attend the meeting and need special assistance, such as sign language interpretation or other special accommodations, should contact Ms. Torres in advance of the meeting.

Dated: March 17, 1995.

Margery G. Grubb,

Senior Committee Management Specialist, NIH.

[FR Doc. 95–7228 Filed 3–23–95; 8:45 am]

BILLING CODE 4140–01–M

Public Health Service

Agency Forms Submitted to the Office of Management and Budget for Clearance

Each Friday the Public Health Service (PHS) publishes a list of information collection requests under review, in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of these requests, call the PHS Reports Clearance Office on (202)–690–7100.

The following requests have been submitted for review since the list was last published on Friday, March 17.

1. Adverse Experience Reporting for Licensed Biological Products—21 CFR 600—New—This rule enables FDA to take actions necessary for protection of the public health in response to reports of adverse experience related to licensed biological products. *Respondents:* Business or other for-profit, not-for-profit institutions. Send comments to Shannah Koss, Human Resources and Housing Branch, New Executive Office Building, room 10235, Washington, DC 20503.

Title	No. of respondents	No. of responses per respondent	Average burden per response (hrs.)
Reporting: 21 CFR 600.81 ..	91	6.09	8.96
Recordkeeping: 21 CFR 600.80 (*i*)	91	1	37

Estimated total annual burden: 8,329 hours.

2. Alcohol and Drug Services Survey (ADSS)—Pilot Study—New—The Alcohol and Drug Services Survey will gather information required in the formulation of national drug policy through three integrated phases: (I) Telephone survey of 2200 treatment facilities; (II) on-site abstraction of client-level data; (III) client follow-up to determine post-discharge substance abuse, criminal activity, employment, and other social functioning. *Respondents:* Individuals or households; Business or other for-profit; Not-for-profit institutions; Federal Government; State, Local or Tribal Government. Send comments to Shannah Koss, Human Resources and Housing Branch, New Executive Office Building, room 10235, Washington, DC 20503.

Title	No. of respondents	No. of responses per respondent	Average burden per response (hrs.)
Facilities	2040	1.037	0.222
Clients	170	1.94	1.0

Estimated total Annual burden: 800 hours.

3. American Stop Smoking Intervention Study for Cancer Prevention (ASSIST) Interim Evaluation: 1995–96 Supplement to the Current Population Survey—0925–0386—Reinstatement, no change—The ''Tobacco Use'' supplement to the Current Population Survey conducted by the Bureau of the Census will collect data from the civilian non-institutionalized population on smoking status and prevalence, smoking intervention dissemination, and changes in smoking norms and attitudes. The data will be used by the National Cancer Institute to evaluate the effectiveness of the American Stop Smoking Intervention Study for Cancer Prevention (ASSIST), a large scale multi-state demonstration project. *Respondents:* Individuals or households; *Number of Respondents:* 200,000; *Number of Responses per Respondent:* 1; *Average Burden per Response:* .1169 hour; *Estimated Total Annual Burden:* 23,380 hours. Send comments to James Scanlon, Office of the Assistant Secretary for Health, Room 737–F, Humphrey Building, 200 Independence Ave., SW., Washington, DC 20201.

Written comments and recommendations concerning the proposed information collections should be sent within 30 days of this notice directly to the individual designated.

Dated: March 21, 1995.

James Scanlon,

Director, Data Policy Staff, Office of the Assistant Secretary for Health and PHS, Reports Clearance Officer.

[FR Doc. 95–7308 Filed 3–23–95; 8:45 am]

BILLING CODE 4160–01–M

National Toxicology Program (NTP) Public Meeting of the NTP Board of Scientific Counselors' Ad Hoc Working Group To Review the Criteria for Listing Substances in the Biennial Report on Carcinogens (BRC)

A public meeting of the NTP Board of Scientific Counselors' ad hoc Working Group to Review the Criteria for Listing Substances in the Biennial Report on Carcinogens (BRC), will be held on April 24 & 25, 1995, in Washington, DC. The meeting will be held at the Washington Hilton and Towers Hotel, 1919 Connecticut Avenue NW., beginning at 9:00 a.m.

The purpose of the meeting is to receive public comments on the criteria for listing substances in the BRC, and to review and make recommendations on the criteria. The issues to be addressed by this ad hoc group are (1) The adequacy of existing criteria for listing substances in future Reports; and (2) the incorporation of mechanistic data as part of the criteria for listing substances in future Reports which may include the consideration of sensitive sub-